Granted Patent B2

US 12,364,609 · App. 16/468,586 · Granted Jul 22, 2025

Inventors: Yacov Koffler (La Jolla, CA); Shaochen Chen (La Jolla, CA); Mark Tuszynski (La Jolla, CA); Wei Zhu (La Jolla, CA)

Assignee: The Regents of the University of California

A61F2/44A61F2/30771A61F2/30942A61L27/3834A61L27/3856A61L27/3878A61F2002/30062A61F2002/30784A61F2002/30838A61F2002/30985A61F2002/4495A61L2430/38

Abstract

Claims (24)

1. A biomimetic nerve or spinal cord implant comprising:

a three-dimensional (3D) implant body comprising: a first end and a second end formed in a biomimetic shape which mimics structure of a nerve or spinal cord injury site as to host axon organization; and

a plurality of linear channels within the body originating at the first end and terminating at the second end, wherein the plurality of linear channels within the body mimics host axon organization ex vivo and in vivo, wherein the plurality of linear channels comprise a channel wall thickness up to 100 micrometers,

wherein the plurality of linear channels retain their pre-implantation structure for at least 4 weeks in vivo, and

wherein the implant comprises an elastic modulus from about 260 kPa to about 300 kPa.

2. The implant of claim 1 , wherein implant is produced by 3D printing.

3. The implant of claim 1 , further comprising at least one type of stem cell included in the plurality of linear channels, wherein the at least one type of stem cell is a neural stem cell.

4. The implant of claim 3 , wherein the neural stem cell is an embryonic stem cell, a iPSC derived stem cell, a directly differentiated neural stem cell, or a combination thereof.

5. The implant of claim 3 , wherein the at least one type of stem cell is a mesenchymal stem cell.

6. The implant of claim 3 , wherein the stem cell is engineered to express BDNF, NT3, GDNF, or a combination thereof.

7. The implant of claim 1 , wherein the implant comprises polyethylene glycol diacrylate or gelatin methacrylol, or a combination thereof.

8. The implant of claim 1 , wherein the implant is biomimetic to a spinal cord injury.

9. The implant of claim 1 , wherein the implant is biomimetic to a peripheral nerve injury.

10. The implant of claim 1 , wherein the plurality of linear channels comprise microchannels.

11. The implant of claim 10 , wherein the plurality of linear channels comprise a diameter of about 200 micrometers.

12. The implant of claim 1 , wherein the plurality of linear channels are parallel to each other.

13. The implant of claim 1 , wherein the plurality of linear channels are configured to guide regenerating axons from the first end to the second end.

14. The implant of claim 1 , wherein the plurality of linear channels comprise hexagonal cross-sections clustered as a honeycomb structure.

15. The implant of claim 1 , wherein the implant comprises a structure without discrete layers.

16. The implant of claim 15 , wherein the implant is composed of a matrix comprising gelatin methacrylate and Poly(ethylene glycol) diacrylate (PEGDA).

17. The implant of claim 16 , wherein the plurality of linear channels retain their pre-implantation structure for at least 6 months in vivo.

18. The implant of claim 1 , wherein the core comprises gelatin methacrylate, PEGDA, and lithium phenyl-2,4,6-trimethylbenzoylphosphinate.

19. The implant of claim 1 , wherein the plurality of linear channels are aligned parallel relative to a host axon and continuously extend from the first end to the second end.

20. The implant of claim 19 , wherein the plurality of linear channels are spaced apart by about 66 micrometers.

Assignments (1)

Continuity (2)

References Cited (107)